Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management

References

• Leading causes of death in Canada 2022. Statistics Canada. 2022. [cited 14 Feb, 2023] Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401.
   Google Scholar
• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147:e93–621.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists Collaboration, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–415.
   PubMed Web of Science ®Google Scholar
• Gorabi AM, Kiaie N, Hajighasemi S, et al. Statin-induced nitric oxide signaling: mechanisms and therapeutic implications. J Clin Med. 2019;8(12):2051. DOI:10.3390/jcm8122051
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381.
   PubMed Web of Science ®Google Scholar
• Nelson AJ, Haynes K, Shambhu S, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79:1802–1813.
   PubMed Web of Science ®Google Scholar
• Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6:1–9.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrøm SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153–1158.
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38–81.
   PubMed Web of Science ®Google Scholar
• Penson PE, Bruckert E, Marais D, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13:1596–1622.
   PubMed Web of Science ®Google Scholar
• Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National lipid association. J Clin Lipidol. 2023;17:19–39.
   PubMed Web of Science ®Google Scholar
• Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16:361–375.
   PubMed Web of Science ®Google Scholar
• Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124:328–350.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker SK, Jacobson TA, et al. The national lipid association’s muscle safety expert panel. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8:S58–71.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Brinton EA, Ito MK, et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208–215.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can. 2014;66:124–132.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31:179–186.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update. Can J Cardiol. 2016;32:S35–65.
   PubMed Web of Science ®Google Scholar
• Taylor BA, Sanchez RJ, Jacobson TA, et al. Application of the statin-associated muscle symptoms-clinical index to a randomized trial on statin myopathy. J Am Coll Cardiol. 2017;70:1680–1681.
   PubMed Web of Science ®Google Scholar
• Meza-Contreras A, Wenczenovicz C, Ruiz-Arellanos K, et al. Statin intolerance management: a systematic review. Endocrine. 2023;79:430–436.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285–350.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
   PubMed Web of Science ®Google Scholar
• Blazing M, Braunwald E, de Lemos J, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400:832–845.
   PubMed Web of Science ®Google Scholar
• Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213–3223.
   PubMed Web of Science ®Google Scholar
• Gluba-Brzozka A, Franczyk B, Toth PP, et al. Molecular mechanisms of statin intolerance. Arch Med Sci. 2016;12:645–658.
   PubMed Web of Science ®Google Scholar
• Vinci P, Panizon E, Tosoni LM, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021;22(21):22. DOI:10.3390/ijms222111687
   Web of Science ®Google Scholar
• Brunham LR, Baker S, Mammen A, et al. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res. 2018;114:1073–1081.
   PubMed Web of Science ®Google Scholar
• Mombelli G. Statin muscle toxicity and genetic risk factors. Int J Genomics Med. 2013;01(02):01.
   Google Scholar
• Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210:337–343.
   PubMed Web of Science ®Google Scholar
• Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193–202.
   PubMedGoogle Scholar
• Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 1993;90:11825–11829.
   PubMed Web of Science ®Google Scholar
• Li JH, Joy SV, Haga SB, et al. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J Pers Med. 2014;4:147–162.
   PubMedGoogle Scholar
• Genetically guided statin therapy. ClinicalTrials.gov, 2017. [cited 14 Feb, 2023]; Available from: https://clinicaltrials.gov/ct2/show/NCT01894230.
   Google Scholar
• Singh K, Peyser B, Trujillo G, et al. Rationale and design of the SLCO1B1 genotype guided statin therapy trial. Pharmacogenomics. 2016;17:1873–1880.
   PubMed Web of Science ®Google Scholar
• Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374:664–669.
   PubMed Web of Science ®Google Scholar
• Nazir S, Lohani S, Tachamo N, et al. Statin-associated autoimmune myopathy: a systematic review of 100 cases. J Clin Rheumatol. 2017;23:149–154.
   PubMed Web of Science ®Google Scholar
• Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome. A case report. Eur Neurol. 2007;57:232–235.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Spengos K, Karandreas N, et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006;166:1519–1524.
   PubMedGoogle Scholar
• Al-Jubouri MA, Briston PG, Sinclair D, et al. Myxoedema revealed by simvastatin induced myopathy. BMJ. 1994;308:588.
   PubMed Web of Science ®Google Scholar
• Scalvini T, Marocolo D, Cerudelli B, et al. Pravastatin-associated myopathy. Report of a case. Recenti Prog Med. 1995;86:198–200.
   PubMedGoogle Scholar
• Voermans NC, Lammens M, Wevers RA, et al. Statin-disclosed acid maltase deficiency. J Intern Med. 2005;258:196–197.
   PubMed Web of Science ®Google Scholar
• Thirupathi A, de Souza CT. Multi-regulatory network of ROS: the interconnection of ROS, PGC-1 alpha, and AMPK-SIRT1 during exercise. J Physiol Biochem. 2017;73:487–494.
   PubMed Web of Science ®Google Scholar
• Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther. 2007;81:650–653.
   PubMed Web of Science ®Google Scholar
• Gambelli S, Dotti MT, Malandrini A, et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosc Cytol Pathol. 2004;36:85–89.
   PubMedGoogle Scholar
• Kavalipati N, Shah J, Ramakrishan A, et al. Pleiotropic effects of statins. Indian J Endocrinol Metab. 2015;19:554–562.
   PubMedGoogle Scholar
• Moßhammer D, Schaeffeler E, Schwab M, et al. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol. 2014;78:454–466.
   PubMed Web of Science ®Google Scholar
• Vaklavas C, Chatzizisis YS, Ziakas A, et al. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009;202:18–28.
   PubMed Web of Science ®Google Scholar
• Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34:153–162.
   PubMed Web of Science ®Google Scholar
• Qu H, Guo M, Chai H, et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e009835.
   PubMed Web of Science ®Google Scholar
• Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;181:E11–8.
   PubMed Web of Science ®Google Scholar
• Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238:329–335.
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Maffioli P. Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. Drug Des Devel Ther. 2019;13:3647–3655.
   PubMed Web of Science ®Google Scholar
• Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol. 2012;110:526–529.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24–34.
   PubMed Web of Science ®Google Scholar
• Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8:333–338.
   PubMed Web of Science ®Google Scholar
• Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10:373–387.
   PubMed Web of Science ®Google Scholar
• Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001;98:14440–14445.
   PubMed Web of Science ®Google Scholar
• Buettner C, Lecker SH. Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics. 2008;9:1133–1142.
   PubMed Web of Science ®Google Scholar
• Mazidi M, Rezaie P, Vatanparast H, et al. Effect of statins on serum vitamin D concentrations: a systematic review and meta-analysis. Eur J Clin Invest. 2017;47:93–101.
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B. Vitamin D and muscle function. J Steroid Biochem Mol Biol. 2017;173:313–316.
   PubMed Web of Science ®Google Scholar
• Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111–116.
   PubMed Web of Science ®Google Scholar
• Bartlomiejczyk M, Penson P, Banach M. Vitamin D and SAMS. In: Thompson P, and Taylor B, editors. Statin-associated muscle symptoms. Totowa, New Jersey: Humana Press; 2020. p. 121–128.
   Google Scholar
• Hlatky MA, Gonzalez PE, Manson JE, et al. Statin-Associated muscle symptoms among new statin users randomly assigned to vitamin D or placebo. JAMA Cardiol. 2023;8:74–80.
   PubMed Web of Science ®Google Scholar
• Reston JT, Buelt A, Donahue MP, et al. Interventions to improve statin tolerance and adherence in patients at risk for cardiovascular disease: a systematic review for the 2020 U.S. Department of veterans affairs and U.S. department of defense guidelines for management of dyslipidemia. Ann Intern Med. 2020;173:806–812.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Lee K, Prince M, et al. Low serum vitamin D, statin associated muscle symptoms, vitamin D supplementation. Atherosclerosis. 2017;256:125–127.
   PubMed Web of Science ®Google Scholar
• Noyes AM, Thompson PD. The effects of statins on exercise and physical activity. J Clin Lipidol. 2017;11:1134–1144.
   PubMed Web of Science ®Google Scholar
• Allard NAE, Timmers S. The role of the mitochondria in SAMS. In: Thompson P Taylor B, editors. Statin-associated muscle symptoms. Cham: Springer International Publishing; 2020. p. 105–112.
   Google Scholar
• Penson PE, Mancini GBJ, Toth PP, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9:1023–1033.
   PubMed Web of Science ®Google Scholar
• Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016;10:739–747.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580–1590.
   PubMed Web of Science ®Google Scholar
• Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389:2473–2481.
   PubMed Web of Science ®Google Scholar
• Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301–310.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy A, Bradley C, Ascunce R, et al. SAMSON and the nocebo effect: management of statin intolerance. Curr Cardiol Rep. 2022;24:1101–1108.
   PubMed Web of Science ®Google Scholar
• Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78:1210–1222.
   PubMed Web of Science ®Google Scholar
• Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135.
   PubMedGoogle Scholar
• Jacobson TA. NLA task force on statin safety–2014 update. J Clin Lipidol. 2014;8:S1–4.
   PubMed Web of Science ®Google Scholar
• Statin intolerance pathway. National Health Service England. 2022. [cited 14 Feb, 2023]; Available from: https://www.england.nhs.uk/aac/publication/statin-intolerance-pathway/
   Google Scholar
• Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian working group consensus conference. Can J Cardiol. 2011;27:635–662.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update. Can J Cardiol. 2013;29:1553–1568.
   PubMed Web of Science ®Google Scholar
• Mancini GBJ, Bergeron J, Fitchett D, et al. The Canadian consensus working group’s approach to identifying and managing statin-associated muscle and other symptoms. In: Thompson P, and Taylor B, editors. Statin-associated muscle symptoms. Cham: Springer International Publishing; 2020. p. 137–150.
   Google Scholar
• Chien SC, Chen PS, Huang YH, et al. 2019 Taiwan society of lipids and atherosclerosis expert consensus statement on statin intolerance. J Formos Med Assoc. 2019;118:1385–1392.
   PubMed Web of Science ®Google Scholar
• Sposito AC, Faria Neto JR, Carvalho LS, et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Curr Med Res Opin. 2017;33:239–251.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition position paper from an international lipid expert panel. Arch Med Sci. 2015;11:1–23.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–414.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Tsimikas S. Lipid-Lowering Agents. Circ Res. 2019;124:386–404. DOI:10.1161/CIRCRESAHA.118.313171
   PubMed Web of Science ®Google Scholar
• Danilov A, Frishman WH, Aronow WS. Antihyperlipidemic Treatment options in statin resistance and intolerance. Cardiol Rev. 2022. DOI:10.1097/CRD.0000000000000498
   PubMedGoogle Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2022;80:1366–1418.
   PubMed Web of Science ®Google Scholar
• Bosco G, Di Giacomo Barbagallo F, Spampinato S, et al. Management of statin intolerant patients in the era of novel lipid lowering therapies: a critical approach in clinical practice. J Clin Med. 2023;12(6):12. DOI:10.3390/jcm12062444
   Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400:380–390.
   PubMed Web of Science ®Google Scholar
• Oyama K, Giugliano RP, Tang M, et al. Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial. Eur Heart J. 2021;42:4821–4829.
   PubMed Web of Science ®Google Scholar
• Sinnaeve PR, Schwartz GG, Wojdyla DM, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020;41:2248–2258.
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. J Clin Lipidol. 2020;14:88–97 e2.
   PubMed Web of Science ®Google Scholar
• Qian LJ, Gao Y, Zhang YM, et al. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: a meta-analysis of 15 randomized controlled trials. Sci Rep. 2017;7:238.
   PubMed Web of Science ®Google Scholar
• Wong ND, Bang M, Block RC, et al. Perceptions and barriers on the use of proprotein subtilisin/kexin type 9 inhibitors in heterozygous familial hypercholesterolemia (From a survey of primary care physicians and cardiologists). Am J Cardiol. 2021;152:57–62.
   PubMed Web of Science ®Google Scholar
• Kaufman TM, Warden BA, Minnier J, et al. Application of PCSK9 Inhibitors in Practice. Circ Res. 2019;124:32–37.
   PubMed Web of Science ®Google Scholar
• Donald DR, Reynolds VW, Hall N, et al. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model. J Clin Lipidol. 2022;16:315–324.
   PubMed Web of Science ®Google Scholar
• Brandts J, Ray KK. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. Curr Opin Lipidol. 2020;31:182–186.
   PubMed Web of Science ®Google Scholar
• Khan SA, Naz A, Qamar Masood M, et al. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020;134:69–73.
   PubMed Web of Science ®Google Scholar
• Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11:109–119.
   PubMedGoogle Scholar
• Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30:1–9.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Louie MJ, et al. Factors associated with enhanced low-density lipoprotein cholesterol lowering with bempedoic acid. J Am Heart Assoc. 2022;11:e024531.
   PubMed Web of Science ®Google Scholar
• Laufs U, Ballantyne CM, Banach M, et al. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022;16:286–297.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353–1364.
   PubMed Web of Science ®Google Scholar
• Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis. 2023. DOI:10.1016/j.pcad.2023.03.001
   PubMedGoogle Scholar
• Warden BA, Cardiology BA, Purnell JQ, et al. Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol. 2022;16:94–103.
   PubMed Web of Science ®Google Scholar
• Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387:1923–1934.
   PubMed Web of Science ®Google Scholar
• Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18:1261–1268.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Botha TC, Raal FJ. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol. 2021;32:213–218.
   PubMed Web of Science ®Google Scholar
• Reeskamp LF, Nurmohamed NS, Bom MJ, et al. Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis. 2021;327:13–17.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ray KK, Nelson AJ, et al. Can we revive CETP-inhibitors for the prevention of cardiovascular disease? Curr Opin Lipidol. 2022;33:319–325.
   PubMed Web of Science ®Google Scholar
• Tombling BJ, Zhang Y, Huang YH, et al. The emerging landscape of peptide-based inhibitors of PCSK9. Atherosclerosis. 2021;330:52–60.
   PubMed Web of Science ®Google Scholar
• Salaheldin TA, Godugu K, Bharali DJ, et al. Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia. Nanomedicine. 2022;40:102480.
   PubMed Web of Science ®Google Scholar
• Momtazi-Borojeni AA, Jaafari MR, Afshar M, et al. PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis. Arch Med Sci. 2021;17:1365–1377.
   PubMed Web of Science ®Google Scholar
• Whittaker MN, Musunuru K. Therapeutic application of genome editing in dyslipidemia. Curr Opin Lipidol. 2022;33:133–138.
   PubMed Web of Science ®Google Scholar
• Banach M, Patti AM, Giglio RV, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:96–118.
   PubMed Web of Science ®Google Scholar
• Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–1693.
   PubMed Web of Science ®Google Scholar
• Marazzi G, Campolongo G, Pelliccia F, et al. Comparison of low-dose statin versus low-dose statin + armolipid plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE Trial). Am J Cardiol. 2017;120:893–897.
   PubMed Web of Science ®Google Scholar
• Laffin LJ, Bruemmer D, Garcia M, et al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers. J Am Coll Cardiol. 2023;81:1–12.
   PubMed Web of Science ®Google Scholar